Vanguard Group
MRTX

Vanguard Group’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Vanguard Group’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-5,306,693
Closed -$312M – 4541
2023
Q4 		$312M Sell
5,306,693
-392,939
-7% -$22.1M 0.01% 1262
2023
Q3 		$248M Buy
5,699,632
+721,357
+14% +$25.8M 0.01% 1320
2023
Q2 		$180M Sell
4,978,275
-71,100
-1% -$2.93M ﹤0.01% 1518
2023
Q1 		$188M Buy
5,049,375
+75,487
+2% +$3.4M ﹤0.01% 1482
2022
Q4 		$225M Buy
4,973,888
+245,589
+5% +$15.9M 0.01% 1365
2022
Q3 		$330M Buy
4,728,299
+180,278
+4% +$13.3M 0.01% 1072
2022
Q2 		$305M Buy
4,548,021
+65,211
+1% +$4.15M 0.01% 1161
2022
Q1 		$369M Buy
4,482,810
+43,833
+1% +$4.48M 0.01% 1169
2021
Q4 		$651M Buy
4,438,977
+301,120
+7% +$46.8M 0.01% 842
2021
Q3 		$732M Buy
4,137,857
+3,434
+0.1% +$552K 0.02% 768
2021
Q2 		$668M Sell
4,134,423
-52,762
-1% -$8.47M 0.02% 818
2021
Q1 		$717M Buy
4,187,185
+154,947
+4% +$30.7M 0.02% 758
2020
Q4 		$886M Buy
4,032,238
+688,116
+21% +$149M 0.03% 621
2020
Q3 		$555M Sell
3,344,122
-105,080
-3% -$14.4M 0.02% 732
2020
Q2 		$394M Buy
3,449,202
+45,764
+1% +$4.44M 0.01% 867
2020
Q1 		$262M Buy
3,403,438
+335,827
+11% +$30.1M 0.01% 971
2019
Q4 		$395M Buy
3,067,611
+29,890
+1% +$2.88M 0.01% 952
2019
Q3 		$237M Buy
3,037,721
+53,215
+2% +$4.99M 0.01% 1232
2019
Q2 		$307M Buy
2,984,506
+802,468
+37% +$62.5M 0.01% 1086
2019
Q1 		$160M Buy
2,182,038
+750,022
+52% +$51M 0.01% 1488
2018
Q4 		$60.7M Buy
1,432,016
+111
+0% +$4.42K ﹤0.01% 1927
2018
Q3 		$67.4M Buy
1,431,905
+26,316
+2% +$1.47M ﹤0.01% 1993
2018
Q2 		$69.3M Buy
1,405,589
+387,198
+38% +$14.6M ﹤0.01% 1953
2018
Q1 		$31.3M Sell
1,018,391
-1,523
-0.1% -$42.3K ﹤0.01% 2321
2017
Q4 		$18.6M Buy
1,019,914
+60,107
+6% +$933K ﹤0.01% 2516
2017
Q3 		$11.2M Buy
959,807
+308,390
+47% +$1.78M ﹤0.01% 2755
2017
Q2 		$2.38M Sell
651,417
-33,698
-5% -$129K ﹤0.01% 3331
2017
Q1 		$3.56M Buy
685,115
+161,303
+31% +$884K ﹤0.01% 3187
2016
Q4 		$2.49M Sell
523,812
-227,885
-30% -$1.24M ﹤0.01% 3291
2016
Q3 		$4.97M Buy
751,697
+127,653
+20% +$679K ﹤0.01% 3012
2016
Q2 		$3.41M Buy
624,044
+67,729
+12% +$1.08M ﹤0.01% 3162
2016
Q1 		$11.9M Buy
556,315
+22,424
+4% +$501K ﹤0.01% 2518
2015
Q4 		$16.9M Buy
533,891
+113,467
+27% +$4.01M ﹤0.01% 2377
2015
Q3 		$14.5M Buy
420,424
+127,662
+44% +$3.86M ﹤0.01% 2424
2015
Q2 		$9.21M Buy
292,762
+14,208
+5% +$419K ﹤0.01% 2720
2015
Q1 		$8.17M Buy
278,554
+62,538
+29% +$1.47M ﹤0.01% 2744
2014
Q4 		$4M Buy
216,016
+1,658
+0.8% +$28K ﹤0.01% 3008
2014
Q3 		$3.75M Buy
214,358
+4,260
+2% +$79.5K ﹤0.01% 2988
2014
Q2 		$4.2M Buy
210,098
+16,848
+9% +$325K ﹤0.01% 2926
2014
Q1 		$3.69M Buy
193,250
+14,069
+8% +$292K ﹤0.01% 2974
2013
Q4 		$2.98M Buy
179,181
+157,449
+725% +$2.69M ﹤0.01% 3031
2013
Q3 		$329K Buy
+21,732
New +$214K ﹤0.01% 3615

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

Vanguard Group's MRTX Position: Q1 2024 in Review

Vanguard Group sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 5,306,693 shares — an estimated $312M sold.

Vanguard Group first reported a position in MRTX in Q3 2013 and held it in 42 quarters. The position peaked at $886M in Q4 2020. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • Vanguard Group reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Vanguard Group sold 5,306,693 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $312M.
  • Vanguard Group first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2013 and held it in 42 quarters.
  • Vanguard Group's Mirati Therapeutics, Inc. Common Stock position peaked at $886M in Q4 2020.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Vanguard Group's 13F filing for Q1 2024, filed 10 May 2024.